Development of alpha-emitting radionuclide lead 212 for the potential treatment of ovarian carcinoma

Journal Article · Sat Apr 01 04:00:00 EST 1989 · Am. J. Obstet. Gynecol.; (United States)

DOI:https://doi.org/10.1016/0002-9378(89)90293-7· OSTI ID:6075811

Rotmensch, J; Atcher, R W; Hines, J; Grdina, D; Schwartz, J S; Toohill, M; Herbst, A L

alpha-Emitting radionuclides may be an effective alternative treatment against ovarian carcinoma because they have short half-lives and are densely ionizing, with high linear energy transfer to a depth of several cell diameters without requiring cellular oxygenation. One radionuclide that has been generated and tested in our laboratory in vitro and in vivo is lead 212 (/sup 212/Pb). Intraperitoneal instillation of /sup 212/Pb prolonged survival and totally eradicated tumor in 24% of mice inoculated with the extremely virulent Ehrlich ascites-producing tumor. In vitro /sup 212/Pb was two to four times more effective in killing human ovarian cancer cells than x-rays. Irradiation with /sup 212/Pb increased the radiosensitivity and chromosomal aberrations of cells. In dogs, intraperitoneal instillation of 2.6 mCi of ferrous hydroxide tagged with /sup 212/Pb caused no significant toxicity. It appears that alpha-emitting radionucides such as /sup 212/Pb have the potential to be a new and potent treatment of ovarian carcinoma and could be effective in cases that are resistant to conventional chemotherapy or x-ray therapy.

• Research Organization: Univ. of Chicago Pritzker School of Medicine, IL (USA)
• OSTI ID: 6075811
• Journal Information: Am. J. Obstet. Gynecol.; (United States), Journal Name: Am. J. Obstet. Gynecol.; (United States) Vol. 160:4; ISSN AJOGA
• Country of Publication: United States
• Language: English

Related Subjects

550603* -- Medicine-- External Radiation in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
ANIMALS
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BIOLOGICAL HALF-LIFE
BODY
CARCINOMAS
DISEASES
EHRLICH ASCITES TUMOR
ENERGY TRANSFER
EVEN-EVEN NUCLEI
EXPERIMENTAL NEOPLASMS
FEMALE GENITALS
GONADS
HEAVY NUCLEI
HOURS LIVING RADIOISOTOPES
INJECTION
INTAKE
INTRAPERITONEAL INJECTION
ISOTOPES
LEAD 212
LEAD ISOTOPES
LET
MAMMALS
MEDICINE
MICE
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ORGANS
OVARIES
RADIOISOTOPES
RADIOLOGY
RADIOSENSITIVITY
RADIOTHERAPY
RODENTS
SURVIVAL CURVES
THERAPY
TOXICITY
VERTEBRATES